stockportfolio.pro
Stocks / CGON vs PACS
CGON vs PACS
CG Oncology, Inc. and PACS Group, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| CG Oncology, Inc. (CGON) | PACS Group, Inc. (PACS) | |
|---|---|---|
| Market cap | $5.1B | $5.5B |
| Revenue (latest FY) | $4.04M | $5.29B |
| Net income (latest FY) | $-161.00M | $191.54M |
| Revenue growth (5y CAGR) | 176.6% | 29.7% |
| Net margin | -3985.0% | 3.6% |
| Return on equity | -21.4% | 20.2% |
| P/E ratio | — | 22.3 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 4 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CGON — free Open PACS — freeFrequently asked questions
Which is bigger, CGON or PACS?
PACS Group, Inc. is larger by market capitalization — $5.5B versus $5.1B.
Which grows faster, CGON or PACS?
Over the last five fiscal years, CG Oncology, Inc. grew revenue faster — 176.6%/yr versus 29.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.